What is it about?
An introduction to the central mechanism of incretin-based therapy for T2DM and Obesity illustrated both the convergence and divergence of different Preproglucagon gene-derived peptide signaling in the CNS for Glucagon-like peptide 1 (GLP-1), Glucose-Dependent insulinotropic Polypeptide (GIP), and Glucagon (GCG).
Featured Image
Photo by Denny Müller on Unsplash
Why is it important?
This review preliminarily reviewed the current progress of studying three major incretins, GLP-1, GIP, and GCG (Glucagon), and their central role in energy and metabolism regulation. It further revealed the complexity of GIPR and GCGR signaling in energy and metabolic regulation.
Perspectives
How to completely acknowledge the physiology of incretin in CNS and their different way in multiple organs may unveil the nature of energy metabolism and optimize the objective for the therapy of malnutrition crisis in current epics.
Dr. Song Wen
Shanghai Pudong Hospital
Read the Original
This page is a summary of: Targeting central pathway of Glucose‐Dependent Insulinotropic Polypeptide, Glucagon and Glucagon‐like Peptide‐1 for metabolic regulation in obesity and type 2 diabetes, Diabetes Obesity and Metabolism, December 2024, Wiley,
DOI: 10.1111/dom.16146.
You can read the full text:
Resources
Contributors
The following have contributed to this page
